| Symbol |
ATP13A2 |
| Full Name |
ATPase Cation Transporting 13A2 |
| Chromosome |
1p36.13 |
| NCBI Gene |
9917 |
| Ensembl |
ENSG00000159363 |
| OMIM |
610513 |
| UniProt |
Q9BYU8 |
| Protein Size |
3,978 amino acids |
| Molecular Weight |
~446 kDa |
| Subcellular Location |
Lysosomes, Late endosomes |
| Diseases |
[PD](/diseases/parkinsons-disease), [Kufor-Rakeb Syndrome](/diseases/kufor-rakeb-syndrome), [Neuronal Ceroid Lipofuscinosis](/diseases/neuronal-ceroid-lipofuscinosis) |
| Expression |
Substantia nigra, Basal ganglia, Cerebral cortex |
| G877R, G887R, W1215X, D501N, A1000P |
ATP13A2 (also known as PARK9) encodes a P5B-type ATPase cation transporter that is primarily localized to lysosomal and late endosomal membranes. This transmembrane protein is critically involved in maintaining cation homeostasis within the lysosomal lumen, particularly for manganese (Mn2+), zinc (Zn2+), and iron (Fe2+/Fe3+). ATP13A2 is highly expressed in brain regions vulnerable to neurodegeneration in Parkinson's disease (PD), including the substantia nigra pars compacta, basal ganglia, and cerebral cortex.
The gene was first implicated in neurodegenerative disease when homozygous loss-of-function mutations were identified as the cause of Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of parkinsonism. Subsequent research has revealed that ATP13A2 plays broader roles in lysosomal function, autophagy, metal homeostasis, and neuronal survival—pathways central to the pathogenesis of both familial and sporadic PD.
ATP13A2 belongs to the P-type ATPase family, specifically the P5B subfamily, which is characterized by the transport of transition metal cations across biological membranes. The protein contains 10 transmembrane domains that form a channel for cation passage, with conserved phosphorylation and ATP-binding domains typical of P-type ATPases.
The primary physiological substrate of ATP13A2 appears to be manganese, although the protein can also transport zinc and potentially other cations. Lysosomal manganese transport is essential for neuronal health because:
-
Manganese sequestration: Lysosomes serve as the primary storage compartment for excess manganese in neurons. Proper sequestration prevents cytoplasmic manganese accumulation that would otherwise cause oxidative stress and mitochondrial dysfunction.
-
Metal homeostasis: Dysregulation of manganese homeostasis leads to manganism, a neurological disorder with parkinsonian features, highlighting the critical importance of proper manganese handling in the basal ganglia.
-
Zinc signaling: ATP13A2-mediated zinc transport may modulate synaptic zinc signaling, which is important for synaptic plasticity and neuronal communication.
¶ Autophagy and Lysosomal Function
ATP13A2 is a key regulator of the autophagy-lysosomal pathway, which is essential for clearing protein aggregates, damaged organelles, and cellular debris. Loss of ATP13A2 function impairs:
- Autophagic flux: Studies show that ATP13A2 knockdown reduces autophagosome formation and impairs the degradation of autophagic substrates.
- Lysosomal proteolytic capacity: ATP13A2 deficiency leads to reduced cathepsin activity and impaired lysosomal function.
- Alpha-synuclein clearance: Impaired autophagy results in decreased clearance of alpha-synuclein, promoting its aggregation—a hallmark of PD pathology.
Emerging evidence suggests ATP13A2 is involved in mitochondrial quality control through its interactions with the PINK1-Parkin pathway. ATP13A2 deficiency leads to:
- Mitochondrial membrane potential loss
- Increased reactive oxygen species (ROS) production
- Impaired mitophagy
- Reduced mitochondrial bioenergetic capacity
Kufor-Rakeb syndrome (KRS) is an autosomal recessive neurodegenerative disorder caused by biallelic loss-of-function mutations in ATP13A2. The syndrome was first described in a Jordanian family from the Kufor-Rakeb region and is characterized by:
- Early-onset parkinsonism: Symptoms typically begin in the second or third decade of life
- Levodopa responsiveness: Patients show significant improvement with dopaminergic therapy
- Pyramidal signs: Spasticity, hyperreflexia, and gait impairment
- Supranuclear gaze palsy: Vertical gaze paralysis is a characteristic feature
- Cognitive decline: Progressive dementia develops in the majority of cases
- Brain iron accumulation: MRI reveals iron deposition in the basal ganglia
The most common disease-causing mutations include:
- G877R: Missense mutation in the ATP-binding domain
- G887R: Missense mutation affecting protein stability
- W1215X: Nonsense mutation creating a premature stop codon
- D501N: Missense mutation in the catalytic domain
- A1000P: Missense mutation affecting transmembrane regions
While KRS is caused by complete loss of ATP13A2 function, more common genetic variants in ATP13A2 have been associated with sporadic Parkinson's disease risk. GWAS and candidate gene studies suggest:
- Modest effect size: Common ATP13A2 variants contribute modestly to overall PD risk
- Gene-environment interactions: The effect may be modified by environmental exposures, particularly to manganese
- Lysosomal dysfunction: ATP13A2 variants may confer risk through subtle impairment of lysosomal function
Recessive ATP13A2 mutations can cause a form of NCL characterized by:
- Lysosomal storage of lipofuscin-like material
- Progressive visual loss
- Seizures
- Developmental regression
- Childhood onset
This overlap between KRS and NCL suggests that ATP13A2 is essential for proper lysosomal function across multiple cell types.
ATP13A2 shows highest expression in:
- Substantia nigra pars compacta: Dopaminergic neurons that degenerate in PD
- Basal ganglia: caudate nucleus, putamen, globus pallidus
- Cerebral cortex: Particularly layer 5 pyramidal neurons
- Hippocampus: CA1 and CA3 regions
- Cerebellum: Purkinje cells
Peripheral expression is also notable in:
- Liver: Hepatocytes
- Kidney: Renal tubules
- Pancreas: Islet cells
This brain-region-specific expression pattern explains the selective vulnerability of dopaminergic neurons in the substantia nigra.
ATP13A2 interacts with several proteins relevant to neurodegeneration:
- PINK1: Both involved in mitochondrial quality control; PINK1 activates mitophagy while ATP13A2 supports mitochondrial function
- Parkin: Cooperates in mitophagy pathway
- Alpha-synuclein: ATP13A2 deficiency promotes alpha-synuclein aggregation
- LAMP2A: Component of chaperone-mediated autophagy
- Cathepsins: Lysosomal proteases whose activity depends on proper lysosomal pH maintained by ATP13A2
ATP13A2 represents a promising therapeutic target for PD:
- Gene therapy: AAV-mediated delivery of ATP13A2 could restore function in patients with loss-of-function mutations
- Small molecule activators: Compounds that enhance ATP13A2 transport activity could benefit patients with partial loss of function
- Autophagy enhancement: Drugs that boost autophagy may compensate for ATP13A2 deficiency
- Metal chelation: For patients with manganese dyshomeostasis, chelation therapy may provide benefit
Several animal models have been developed to study ATP13A2 function:
- C. elegans: Knockout models show enhanced sensitivity to manganese toxicity
- Mouse models: Global and conditional knockouts demonstrate motor deficits and alpha-synuclein pathology
- Drosophila: Loss of ATP13A2 homolog leads to neurodegeneration and shortened lifespan
Single-cell RNA sequencing data from the Allen Brain Atlas shows ATP13A2 expression in:
- Substantia nigra pars compacta: High expression in dopaminergic neurons, particularly vulnerable in Parkinson's disease
- Cerebral cortex: Moderate expression across cortical layers, with higher expression in deeper layers (L5-L6)
- Basal ganglia: Expression in striatal medium spiny neurons and globus pallidus
- Hippocampus: Expression in CA regions and dentate gyrus granule cells
- Microglia: Low to moderate expression in immune cells
Key observations from Allen Brain Atlas human tissue data:
- ATP13A2 is highly expressed in brain regions affected in PD, supporting its role in disease pathogenesis
- Expression is enriched in neurons compared to glial cells
- The gene shows regional specificity consistent with the pattern of neurodegeneration observed in KRS and PD
External Resources:
The P5B-type ATPases like ATP13A2 undergo a characteristic catalytic cycle involving phosphorylation of an aspartate residue in the DKTGTLT motif. This cycle consists of several key steps:
- E1 ~ P state: ATP binding and phosphorylation of the conserved aspartate
- E2-P state: Conformational change transferring the phosphate
- E2-P open state: Cation binding from the lumen
- E1 ~ P state: Dephosphorylation and release of cation to the cytoplasm
This cycle is powered by ATP hydrolysis and allows vectorial transport of cations against their electrochemical gradient.
¶ Lysosomal pH Maintenance
ATP13A2 plays a crucial role in maintaining lysosomal pH, which is essential for the activity of hydrolytic enzymes:
- V-ATPase dependence: Lysosomes normally rely on V-ATPases for proton pumping
- ATP13A2 compensation: ATP13A2 may provide complementary cation transport that helps maintain electrochemical balance
- pH gradient: Proper pH (4.5-5.0) is required for cathepsin activation
- Implications: Loss of ATP13A2 leads to alkalinized lysosomes and impaired degradation
Detailed biochemical studies have revealed:
- Manganese (Mn2+): Highest affinity substrate, Km ~ 10-20 μM
- Zinc (Zn2+): Lower affinity, Km ~ 50-100 μM
- Iron (Fe2+): Variable affinity depending on oxidation state
- Calcium (Ca2+): May serve as alternate substrate at high concentrations
The transport kinetics are modulated by:
- Intra-luminal metal concentration
- Lysosomal membrane potential
- ATP availability
- pH gradient across the lysosomal membrane
Loss of ATP13A2 function leads to progressive lysosomal storage abnormalities:
- Lipofuscin accumulation: Ceroid-like material accumulates in neurons
- Autophagic vacuoles: Empty autophagic vesicles accumulate
- Lysosomal membrane expansion: Abnormal lysosomal morphology
- Impaired cargo degradation: Reduced turnover of autophagy substrates
These storage abnormalities are reminiscent of neuronal ceroid lipofuscinoses, explaining the phenotypic overlap.
ATP13A2 deficiency causes widespread metal dysregulation:
- Manganese: Accumulation in cytosol and mitochondria
- Zinc: Altered synaptic zinc handling
- Iron: Increased free iron leading to Fenton chemistry
- Copper: Potential dysregulation of copper trafficking
The cytoplasmic manganese accumulation is particularly toxic, causing:
Mitochondrial abnormalities in ATP13A2 deficiency include:
- Complex I deficiency: Reduced activity of NADH dehydrogenase
- Membrane potential loss: Decreased ΔΨm
- ROS overproduction: Increased superoxide and hydrogen peroxide
- DNA damage: Mitochondrial DNA mutations accumulate
- Apoptosis susceptibility: Enhanced sensitivity to cell death signals
ATP13A2 loss promotes aggregation of several proteins relevant to PD:
- Alpha-synuclein: Enhanced aggregation and toxicity
- Tau: Hyperphosphorylation and aggregation
- LRRK2: Altered kinase activity
- Ubiquitin: Accumulation of ubiquitinated proteins
The bidirectional relationship between ATP13A2 and alpha-synuclein is particularly significant, with each protein's aggregation promoting the other's pathology.
ATP13A2 deficiency triggers robust neuroinflammatory responses:
- Microglial activation: Iba-1 positive microglia proliferate
- Cytokine release: IL-1β, TNF-α, IL-6 elevated
- Complement activation: C1q and C3b deposition
- NLRP3 inflammasome: Caspase-1 activation
This neuroinflammation creates a feed-forward loop promoting further neurodegeneration.
The complete clinical picture of KRS includes:
Motor Symptoms:
- Bradykinesia (slowness of movement)
- Rigidity (muscle stiffness)
- Resting tremor
- Postural instability
- Gait freezing
- Facial masking
Non-Motor Symptoms:
- Cognitive decline (dementia in 70%)
- Psychiatric features (depression, anxiety, psychosis)
- Sleep disorders (REM sleep behavior disorder)
- Autonomic dysfunction (orthostatic hypotension)
- Sensory abnormalities (anosmia, pain)
Neurological Signs:
- Supranuclear gaze palsy (vertical > horizontal)
- Pyramidal tract signs (hyperreflexia, spasticity)
- Cerebellar signs (ataxia, dysmetria)
- Cortical sensory loss
Neuroimaging Findings:
- MRI: Iron deposition in basal ganglia, cerebral atrophy
- PET: Reduced dopamine transporter binding
- SPECT: Normal or reduced cerebral blood flow
KRS typically follows a progressive course:
- Early stage (ages 10-20): Subtle motor signs, learning difficulties
- Middle stage (ages 20-30): Clear parkinsonism, gaze palsy emerges
- Late stage (ages 30+): Severe disability, dementia, complete dependence
Mean disease duration is 20-30 years, with death typically from aspiration pneumonia or complications of immobility.
Different mutations show variable phenotypes:
- Null mutations (W1215X): Severe, early-onset KRS
- Missense mutations (G877R, G887R): Variable severity
- Partial loss-of-function: Late-onset, milder parkinsonism
- Compound heterozygotes: Intermediate phenotypes
Over 30 pathogenic variants have been described:
| Mutation Type |
Examples |
Effect |
| Missense |
G877R, G887R, D501N |
Reduced activity |
| Nonsense |
W1215X, Q474X |
Truncated protein |
| Frameshift |
c.3050delC |
Null allele |
| Splice site |
c.1844-1G>A |
Aberrant splicing |
| Large deletion |
Exon 15-16 del |
No functional protein |
- Prevalence: Very rare, < 1 per million
- Founder mutations: Reported in Jordanian, Chilean, and other populations
- Carrier frequency: Extremely low in general populations
- Consanguinity: Common in affected families (autozygous segments)
Clinical testing options include:
- Targeted panel: Parkin, PINK1, DJ-1, ATP13A2, etc.
- Whole exome sequencing: Broader differential diagnosis
- Copy number analysis: Detects large deletions
- Functional assays: In vitro transport assays
KRS should be suspected in:
- Early-onset parkinsonism (< 30 years)
- Additional features: gaze palsy, pyramid signs
- Family history (consanguinity)
- Lack of response to typical PD medications
Potential biomarkers under investigation:
- Blood manganese: Often elevated
- Lysosomal enzymes: Reduced activity
- Neurofilament light chain: Elevated in CSF
- Neuroimaging: Characteristic patterns
Other early-onset parkinsonism:
- Juvenile Parkinsonism ( PARK2/Parkin)
- PINK1-associated PD
- DJ-1-associated PD
- ATP13A2-associated PD (KRS)
- Wilson disease
- Huntington disease
Dopaminergic therapy:
- Levodopa/carbidopa: First-line
- Dopamine agonists: Pramipexole, ropinirole
- MAO-B inhibitors: Selegiline, rasagiline
- COMT inhibitors: Entacapone
Non-motor symptoms:
- Antidepressants: SSRIs
- Antipsychotics: Clozapine (low dose)
- Sleep medications: Melatonin, clonazepam
Neuroprotective strategies:
- Coenzyme Q10
- Vitamin E
- NMDA antagonists
- Calcium channel blockers
- Deep brain stimulation: Effective for motor fluctuations
- Target selection: STN or GPi
- Outcome: Significant improvement in motor scores
- Complications: Hardware issues, neuropsychiatric effects
Gene therapy:
- AAV-ATP13A2 delivery to putamen
- Potential for disease modification
- Currently in preclinical development
Protein therapy:
- Recombinant ATP13A2 delivery
- Enzyme replacement concept
- Challenges: lysosomal targeting
Small molecules:
- Transport activity enhancers
- Pharmacological chaperones
- Autophagy modulators
- Patient fibroblasts: Elevated lysosomal pH, impaired autophagy
- iPSC-derived neurons: Show mitochondrial dysfunction
- Knockdown cell lines: Used for mechanism studies
- Overexpression systems: For functional characterization
Mouse models:
- Global knockout: Motor deficits, alpha-synuclein pathology
- Conditional knockout: Region-specific phenotypes
- Transgenic: Human ATP13A2 expression
Non-mammalian models:
- C. elegans: Simple behavioral assays
- Drosophila: Genetic interaction studies
- Zebrafish: Developmental studies
- Transport assays: Radioisotope uptake
- ATPase assays: Phosphate release
- pH measurements: Lysosomal pH sensors
- Immunofluorescence: Protein localization
Current trials investigating:
- Gene therapy approaches: AAV-mediated ATP13A2 delivery
- Autophagy enhancers: Rapamycin analogs
- Metal chelation: EDTA, CaNa2EDTA for manganese
- Neuroprotective agents: CoQ10, creatine
Key research priorities:
- Understanding structure-function relationships
- Developing better animal models
- Identifying biomarkers
- Clinical trial design for rare diseases
- Gene therapy optimization
ATP13A2 (PARK9) encodes a lysosomal P5B-type ATPase critical for metal cation transport, lysosomal function, and neuronal survival. Biallelic mutations cause Kufor-Rakeb syndrome, an early-onset parkinsonism with additional neurological features. The protein plays essential roles in:
- Lysosomal manganese and zinc transport
- Autophagy and protein clearance
- Mitochondrial quality control
- Metal homeostasis
Understanding ATP13A2 function provides insights into the broader pathogenesis of Parkinson's disease and identifies potential therapeutic targets.
ATP13A2 dysfunction exemplifies the growing recognition that lysosomal dysfunction is central to Parkinson's disease pathogenesis:
- GBA mutations: Heterozygous GBA variants increase PD risk 5-fold
- ATP13A2: Loss of function causes lysosomal impairment
- LRRK2: May affect lysosomal trafficking
- SNCA: Alpha-synuclein accumulation disrupts lysosomes
This creates a feed-forward loop where lysosomal dysfunction promotes alpha-synuclein aggregation, which further impairs lysosomal function.
ATP13A2 variants may interact with environmental risk factors:
- Manganese exposure: Occupational exposure to manganese synergizes with ATP13A2 variants
- Pesticides: Some pesticides may inhibit ATP13A2 function
- Aging: Age-related decline in lysosomal function compounds ATP13A2 deficiency
ATP13A2 orthologs across species:
| Species |
Gene |
Key Features |
| Human |
ATP13A2 |
Full-length P5B ATPase |
| Mouse |
Atp13a2 |
97% similar |
| Zebrafish |
atp13a2 |
Expressed in brain |
| C. elegans |
catp-6 |
Ortholog in neurons |
| Drosophila |
dATP13A2 |
Essential for viability |
Conservation of ATP13A2 underscores its fundamental cellular importance.
The protein structure reveals:
- 10 transmembrane helices: Form cation channel
- Actuator domain (A): Conformational changes
- **Phosphorylation domain (P): Contains DKTGTLT motif
- ATP-binding domain (N): Catalyzes ATP hydrolysis
Cryo-EM structures have revealed:
- Open conformation: Cytoplasm-facing channel
- Closed conformation: Lumen-facing channel
- Intermediate states: Transition intermediates
Current drug development strategies:
- Pharmacological chaperones: Small molecules that stabilize mutant protein
- Transport activators: Increase ATP13A2 activity
- Gene therapy: AAV-delivered ATP13A2
- Protein therapy: Recombinant protein delivery
- Combination approaches: Target multiple pathways
Potential biomarkers for ATP13A2-related disease:
- Blood manganese: Non-specific but elevated
- Lysosomal pH: In patient cells
- Autophagic markers: LC3, p62 levels
- Neurofilament: CSF neurofilament light chain
ATP13A2 sits at the intersection of several disease networks:
- Metal homeostasis network: Manganese, zinc, iron
- Lysosomal network: GBA, LAMP2, NPC1
- Mitophagy network: PINK1, Parkin, FBXO7
- Protein quality control: Ubiquitin, proteasome
This network position explains why ATP13A2 dysfunction affects multiple cellular systems.
ATP13A2-related disease epidemiology:
- Kufor-Rakeb syndrome: < 100 families reported worldwide
- ATP13A2-associated PD: Much more common but underdiagnosed
- Carrier frequency: Extremely rare
- Age of onset: Typically 12-40 years for KRS
Healthcare burden considerations:
- Diagnostic odyssey: Average 5-10 years to diagnosis
- Treatment costs: High due to early onset and long disease duration
- Quality of life: Significant disability in young patients
- Family impact: Multi-generational burden
Genetic testing issues:
- Reproductive counseling: Autosomal recessive inheritance
- Incidental findings: Variants of uncertain significance
- Family testing: Identifies carriers in families
- Privacy concerns: Genetic data protection
ATP13A2 represents a paradigm for understanding lysosomal dysfunction in neurodegeneration. From its role as a lysosomal cation transporter to its involvement in multiple neurodegenerative pathways, ATP13A2 provides critical insights into Parkinson's disease pathogenesis and identifies promising therapeutic targets. Continued research into ATP13A2 function and dysfunction will advance our understanding of neurodegenerative diseases and accelerate the development of effective treatments.